Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 10/20 | 0.57 |
| ▸ | GRM1 | Q13255 | 10/20 | 0.57 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.51 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20955503 | 0.89 | GRM5 (0.59) | GRM5GRM1PDE10APDK4NAMPT | |
| SCHEMBL15941818 | 0.85 | GRM5 (0.59) | GRM5GRM1PDE10APDK4NAMPT | |
| SCHEMBL31306939 | 0.84 | GRM5 (0.61) | GRM5GRM1PDE10APDK4NAMPT | |
| SCHEMBL4001532 | 0.84 | GRM5 (0.63) | GRM5GRM1PDE10APDK4NAMPT | |
| SCHEMBL4000426 | 0.84 | GRM5 (0.60) | GRM5GRM1PDE10APDK4POLB | |
| SCHEMBL73964 | 0.84 | GRM5 (0.60) | GRM5GRM1PDE10APDK4NAMPT | |
| SCHEMBL3791998 | 0.84 | GRM5 (0.71) | GRM5GRM1PDE10APDK4NAMPT | |
| SCHEMBL2422977 | 0.83 | PDK4 (0.57) | GRM5GRM1PDE10APDK4NAMPT | |
| SCHEMBL13473858 | 0.83 | GRM1 (0.48) | GRM5GRM1PDE10APDK4NAMPT | |
| SCHEMBL30736543 | 0.82 | PDK4 (0.64) | GRM5GRM1PDE10APDK4NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11414429-B2 | Compound or pharmaceutically acceptable salt thereof | RIKEN (JP) | 2022-08-16 | — | — | US | disclosed |
| EP-3480198-B1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | RIKEN (JP) | 2021-05-05 | — | — | EP | disclosed |
| US-20200172554-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | RIKEN (JP) | 2020-06-04 | — | — | US | disclosed |
| EP-3480198-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | RIKEN (JP) | 2019-05-08 | — | — | EP | disclosed |
| EP-2550252-B1 | 1-(2-PHENOXYMETHYLHETEROARYL)PIPERIDINE AND PIPERAZINE COMPOUNDS | THERAVANCE BIOPHARMA R & D IP LLC (US) | 2015-05-06 | — | — | EP | disclosed |
| US-8530663-B2 | 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds | THERAVANCE, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530663-B2 | 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds | THERAVANCE, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530663-B2 | 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds | THERAVANCE, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-20110230495-A1 | 1-(2-PHENOXYMETHYLHETEROARYL)PIPERIDINE AND PIPERAZINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2011-09-22 | — | — | US | disclosed |
| US-20110230495-A1 | 1-(2-PHENOXYMETHYLHETEROARYL)PIPERIDINE AND PIPERAZINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2011-09-22 | — | — | US | disclosed |
| US-20110230495-A1 | 1-(2-PHENOXYMETHYLHETEROARYL)PIPERIDINE AND PIPERAZINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230495-A1 | 1-(2-PHENOXYMETHYLHETEROARYL)PIPERIDINE AND PIPERAZINE COMPOUNDS | HTR1A, HTR1D, HTR5A | GRM5 309/4885GRM1 157/4885PDE10A 1780/4885 |
| US-11414429-B2 | Compound or pharmaceutically acceptable salt thereof | DPP8, DPP7, AZI2 | GRM5 467/4885GRM1 688/4885PDE10A 237/4885 |
| US-20200172554-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DPP8, DPP7, AZI2 | GRM5 452/4885GRM1 632/4885PDE10A 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.